Blockade of LTB4-induced chemotaxis by bioactive molecules interfering with the BLT2-Gαi interaction

Joo Young Kim, Won Kyu Lee, Yeon Gyu Yu, Jae-Hong Kim

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

BLT2, a low-affinity leukotriene B4 (LTB4) receptor, is a member of the G-protein coupled receptor (GPCR) family and is involved in the pathogenesis of inflammatory diseases such as asthma. Despite its clinical implications, however, no pharmacological inhibitors are available. In the present study, we screened for small molecules that interfere with the interaction between the third intracellular loop region of BLT2 (BLT2iL3) and the Gαi3 protein subunit (Gαi3), using a high-throughput screening (HTS) assay with a library of 1040 FDA-approved drugs and bioactive compounds. We identified two small molecules-purpurin [1,2,4-trihydroxy-9,10-anthraquinone; IC50 = 1.6 μM for BLT2] and chloranil [tetrachloro-1,4-benzoquinone; IC50 = 0.42 μM for BLT2]-as specific BLT2-blocking agents. We found that blockade of the BLT2iL3-Gαi3 interaction by these small molecules inhibited the BLT2-downstream signaling cascade. For example, BLT2-signaling to phosphoinositide-3 kinase (PI3K)/Akt phosphorylation was completely abolished by these molecules. Furthermore, we observed that these small molecules blocked LTB4-induced chemotaxis by inhibiting the BLT2-PI3K/Akt-downstream, Rac1-reactive oxygen species-dependent pathway. Taken together, our results show that purpurin and chloranil interfere with the interaction between BLT2iL3 and Gαi3 and thus block the biological functions of BLT2 (e.g., chemotaxis). The present findings suggest a potential application of purpurin and chloranil as pharmacological therapeutic agents against BLT2-associated inflammatory human diseases.

Original languageEnglish
Pages (from-to)1506-1515
Number of pages10
JournalBiochemical Pharmacology
Volume79
Issue number10
DOIs
Publication statusPublished - 2010 May 15

Fingerprint

Chloranil
Leukotriene B4
Chemotaxis
Molecules
1-Phosphatidylinositol 4-Kinase
Inhibitory Concentration 50
Phosphatidylinositols
Leukotriene B4 Receptors
Pharmacology
High-Throughput Screening Assays
Phosphotransferases
Protein Subunits
G-Protein-Coupled Receptors
Phosphorylation
Libraries
Reactive Oxygen Species
Asthma
Assays
Screening
Throughput

Keywords

  • BLT2
  • Chemotaxis
  • Chloranil
  • LTB
  • Purpurin

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry

Cite this

Blockade of LTB4-induced chemotaxis by bioactive molecules interfering with the BLT2-Gαi interaction. / Kim, Joo Young; Lee, Won Kyu; Yu, Yeon Gyu; Kim, Jae-Hong.

In: Biochemical Pharmacology, Vol. 79, No. 10, 15.05.2010, p. 1506-1515.

Research output: Contribution to journalArticle

Kim, Joo Young ; Lee, Won Kyu ; Yu, Yeon Gyu ; Kim, Jae-Hong. / Blockade of LTB4-induced chemotaxis by bioactive molecules interfering with the BLT2-Gαi interaction. In: Biochemical Pharmacology. 2010 ; Vol. 79, No. 10. pp. 1506-1515.
@article{cba4913f9ca0420487f6eedcee1ca21b,
title = "Blockade of LTB4-induced chemotaxis by bioactive molecules interfering with the BLT2-Gαi interaction",
abstract = "BLT2, a low-affinity leukotriene B4 (LTB4) receptor, is a member of the G-protein coupled receptor (GPCR) family and is involved in the pathogenesis of inflammatory diseases such as asthma. Despite its clinical implications, however, no pharmacological inhibitors are available. In the present study, we screened for small molecules that interfere with the interaction between the third intracellular loop region of BLT2 (BLT2iL3) and the Gαi3 protein subunit (Gαi3), using a high-throughput screening (HTS) assay with a library of 1040 FDA-approved drugs and bioactive compounds. We identified two small molecules-purpurin [1,2,4-trihydroxy-9,10-anthraquinone; IC50 = 1.6 μM for BLT2] and chloranil [tetrachloro-1,4-benzoquinone; IC50 = 0.42 μM for BLT2]-as specific BLT2-blocking agents. We found that blockade of the BLT2iL3-Gαi3 interaction by these small molecules inhibited the BLT2-downstream signaling cascade. For example, BLT2-signaling to phosphoinositide-3 kinase (PI3K)/Akt phosphorylation was completely abolished by these molecules. Furthermore, we observed that these small molecules blocked LTB4-induced chemotaxis by inhibiting the BLT2-PI3K/Akt-downstream, Rac1-reactive oxygen species-dependent pathway. Taken together, our results show that purpurin and chloranil interfere with the interaction between BLT2iL3 and Gαi3 and thus block the biological functions of BLT2 (e.g., chemotaxis). The present findings suggest a potential application of purpurin and chloranil as pharmacological therapeutic agents against BLT2-associated inflammatory human diseases.",
keywords = "BLT2, Chemotaxis, Chloranil, LTB, Purpurin",
author = "Kim, {Joo Young} and Lee, {Won Kyu} and Yu, {Yeon Gyu} and Jae-Hong Kim",
year = "2010",
month = "5",
day = "15",
doi = "10.1016/j.bcp.2010.01.018",
language = "English",
volume = "79",
pages = "1506--1515",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Blockade of LTB4-induced chemotaxis by bioactive molecules interfering with the BLT2-Gαi interaction

AU - Kim, Joo Young

AU - Lee, Won Kyu

AU - Yu, Yeon Gyu

AU - Kim, Jae-Hong

PY - 2010/5/15

Y1 - 2010/5/15

N2 - BLT2, a low-affinity leukotriene B4 (LTB4) receptor, is a member of the G-protein coupled receptor (GPCR) family and is involved in the pathogenesis of inflammatory diseases such as asthma. Despite its clinical implications, however, no pharmacological inhibitors are available. In the present study, we screened for small molecules that interfere with the interaction between the third intracellular loop region of BLT2 (BLT2iL3) and the Gαi3 protein subunit (Gαi3), using a high-throughput screening (HTS) assay with a library of 1040 FDA-approved drugs and bioactive compounds. We identified two small molecules-purpurin [1,2,4-trihydroxy-9,10-anthraquinone; IC50 = 1.6 μM for BLT2] and chloranil [tetrachloro-1,4-benzoquinone; IC50 = 0.42 μM for BLT2]-as specific BLT2-blocking agents. We found that blockade of the BLT2iL3-Gαi3 interaction by these small molecules inhibited the BLT2-downstream signaling cascade. For example, BLT2-signaling to phosphoinositide-3 kinase (PI3K)/Akt phosphorylation was completely abolished by these molecules. Furthermore, we observed that these small molecules blocked LTB4-induced chemotaxis by inhibiting the BLT2-PI3K/Akt-downstream, Rac1-reactive oxygen species-dependent pathway. Taken together, our results show that purpurin and chloranil interfere with the interaction between BLT2iL3 and Gαi3 and thus block the biological functions of BLT2 (e.g., chemotaxis). The present findings suggest a potential application of purpurin and chloranil as pharmacological therapeutic agents against BLT2-associated inflammatory human diseases.

AB - BLT2, a low-affinity leukotriene B4 (LTB4) receptor, is a member of the G-protein coupled receptor (GPCR) family and is involved in the pathogenesis of inflammatory diseases such as asthma. Despite its clinical implications, however, no pharmacological inhibitors are available. In the present study, we screened for small molecules that interfere with the interaction between the third intracellular loop region of BLT2 (BLT2iL3) and the Gαi3 protein subunit (Gαi3), using a high-throughput screening (HTS) assay with a library of 1040 FDA-approved drugs and bioactive compounds. We identified two small molecules-purpurin [1,2,4-trihydroxy-9,10-anthraquinone; IC50 = 1.6 μM for BLT2] and chloranil [tetrachloro-1,4-benzoquinone; IC50 = 0.42 μM for BLT2]-as specific BLT2-blocking agents. We found that blockade of the BLT2iL3-Gαi3 interaction by these small molecules inhibited the BLT2-downstream signaling cascade. For example, BLT2-signaling to phosphoinositide-3 kinase (PI3K)/Akt phosphorylation was completely abolished by these molecules. Furthermore, we observed that these small molecules blocked LTB4-induced chemotaxis by inhibiting the BLT2-PI3K/Akt-downstream, Rac1-reactive oxygen species-dependent pathway. Taken together, our results show that purpurin and chloranil interfere with the interaction between BLT2iL3 and Gαi3 and thus block the biological functions of BLT2 (e.g., chemotaxis). The present findings suggest a potential application of purpurin and chloranil as pharmacological therapeutic agents against BLT2-associated inflammatory human diseases.

KW - BLT2

KW - Chemotaxis

KW - Chloranil

KW - LTB

KW - Purpurin

UR - http://www.scopus.com/inward/record.url?scp=77649190043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649190043&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2010.01.018

DO - 10.1016/j.bcp.2010.01.018

M3 - Article

C2 - 20097180

AN - SCOPUS:77649190043

VL - 79

SP - 1506

EP - 1515

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 10

ER -